- Home
- AI Drug Discovery Software
- Benevolent Platform
On the recordRead 14 Nov 202613 facts
Benevolent Platform
The company describes itself as headquartered in London.
On the record
- AI and data
- BenevolentAI describes its technology as using multimodal data to surface insights and accelerate biomedical discovery.benevolent.com · read 14 Nov 2026
- Audience
- BenevolentAI says its team supports scientists and executives using AI and machine learning in their work.benevolent.com · read 14 Nov 2026
- Collaborations
- The company names AstraZeneca and Merck among its pharmaceutical discovery collaboration partners.benevolent.com · read 14 Nov 2026
- Contact
- The company provides a press contact email address.benevolent.com · read 14 Nov 2026
- Drug discovery
- The company says it uses its platform, scientific expertise, and wet-lab facilities to accelerate novel drug discovery.benevolent.com · read 14 Nov 2026
- Focus
- In April 2024, BenevolentAI said it would focus on drug discovery collaborations and its proprietary pipeline.benevolent.com · read 14 Nov 2026
- Knowledge Exploration Tools
- The company announced that work on its Knowledge Exploration Tools would cease after a market assessment.benevolent.com · read 14 Nov 2026
- Knowledge graph
- The company says its technology builds on investment in a knowledge graph and proprietary ontologies.benevolent.com · read 14 Nov 2026
- Platform development
- A 2024 company announcement stated that investment would continue in development of the BenevolentAI Platform.benevolent.com · read 14 Nov 2026
- Platform offering
- BenevolentAI describes its platform as integrating AI and science to uncover new biology, predict novel targets, and develop drugs for complex diseases.benevolent.com · read 14 Nov 2026
- Product availability
- The current homepage presents Qor as an always-on strategic function for biopharma decision makers and life science consultancies.benevolent.com · read 14 Nov 2026